Primary Peritoneal Carcinoma Clinical Trial
— CARCINOHIPECOfficial title:
Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial.
The purpose of this clinical trial is to Investigate whether the administration of HIPEC with Cisplatin (75 milligrams per square meter of body surface) after surgical cytoreduction in women with ovarian, tubal or primary peritoneal carcinoma increased disease-free survival period compared with patients without HIPEC treatment.
Status | Recruiting |
Enrollment | 32 |
Est. completion date | December 2018 |
Est. primary completion date | December 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Peritoneal carcinomatosis arising from ovarian epithelial carcinoma (stage III or higher), carcinoma of the fallopian tube and primary peritoneal carcinoma. - Residual tumor < 2.5 mm after completion of cytoreductive surgery. - Aged < 75 years. - Baseline ECOG 0-1 (Eastern Cooperative Oncologic Group). - Adequate bone marrow function with hemoglobin ? 8 g/dl (after correction for iron deficiency anemia), white blood cell count ? 3,000/mm3, platelets ? 100,000/mm3. - Adequate renal function with creatinine ? 1.5 mg/ dl. - Adequate liver function with bilirubin levels ? 1.5 mg / dl and AST and ALT ? 80 IU / L. - Optimal cardiopulmonary function. - In recurrences, disease-free interval > 6 months. - Voluntary and signed written informed consent. Exclusion Criteria: - Extraperitoneal tumor disease. - Suboptimal debulking (residual tumor > 2.5 mm). - Previous history of other malignancies (excluding skin) - Intestinal obstruction at the time of evaluation. - Renal failure. - Heart failure. - Uncontrolled infection. - Pregnant or lactating patients. - In recurrences, disease-free interval < 6 months. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clínico Universitario Virgen de la Arrixaca | El Palmar. | Murcia |
Lead Sponsor | Collaborator |
---|---|
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | disease-free survival period | Every three months until recurrence of disease. | Every 3 months up to 30 months | |
Secondary | Evaluation of overall survival. | Every three months until recurrence of disease. | Every 3 months up to 30 months | |
Secondary | Study of morbidity. | Every three months until recurrence of disease. | Every 3 months up to 30 months | |
Secondary | Evaluation of quality of life related to the procedure. | Every three months until recurrence of disease. | Every 3 months up to 30 months | |
Secondary | Study of Ex vivo correlation. | in vitro cell culture to study the effect of temperature and cisplatin on cell viability | 4 days post surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01442051 -
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
Active, not recruiting |
NCT03648489 -
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
|
Phase 2 | |
Completed |
NCT01031381 -
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
|
Phase 2 | |
Terminated |
NCT01202890 -
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
|
Phase 1 | |
Completed |
NCT00561795 -
Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors
|
Phase 2 | |
Completed |
NCT00301756 -
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
|
Phase 2 | |
Completed |
NCT00066456 -
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
|
Phase 1 | |
Completed |
NCT00045682 -
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
|
Phase 2 | |
Withdrawn |
NCT04368130 -
SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care
|
N/A | |
Terminated |
NCT04814875 -
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
|
Phase 1/Phase 2 | |
Completed |
NCT00989651 -
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Recruiting |
NCT05537844 -
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
|
||
Terminated |
NCT03585764 -
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Completed |
NCT03921658 -
The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
|
||
Completed |
NCT04088786 -
Phase I Trial HIPEC With Nal-irinotecan
|
Phase 1 | |
Withdrawn |
NCT00551265 -
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
|
N/A | |
Completed |
NCT00093626 -
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
|
Phase 2 | |
Completed |
NCT03367260 -
The Treatment Preferences of Women Diagnosed With Ovarian Cancer
|
||
Recruiting |
NCT03983226 -
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)
|
Phase 2 | |
Recruiting |
NCT03373058 -
Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery
|
Phase 3 |